Charles Schwab Investment Management Inc. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM)

Charles Schwab Investment Management Inc. boosted its position in shares of Immunome, Inc. (NASDAQ:IMNM) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 457,252 shares of the company’s stock after purchasing an additional 14,775 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.73% of Immunome worth $4,856,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Intech Investment Management LLC bought a new position in shares of Immunome during the 3rd quarter worth $219,000. Cerity Partners LLC grew its holdings in Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company’s stock worth $776,000 after acquiring an additional 5,043 shares in the last quarter. FMR LLC grew its holdings in Immunome by 0.3% during the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock worth $61,765,000 after acquiring an additional 13,757 shares in the last quarter. MetLife Investment Management LLC increased its position in Immunome by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 30,265 shares of the company’s stock valued at $442,000 after purchasing an additional 17,053 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after purchasing an additional 324,614 shares in the last quarter. 44.58% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CTO Philip Tsai purchased 12,300 shares of the company’s stock in a transaction on Monday, March 24th. The shares were acquired at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares in the company, valued at $280,386. This trade represents a 58.57 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Clay B. Siegall bought 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 169,300 shares of company stock valued at $1,323,536. 8.60% of the stock is currently owned by corporate insiders.

Immunome Stock Down 14.7 %

Shares of IMNM opened at $6.95 on Wednesday. The company has a 50 day moving average of $9.67 and a two-hundred day moving average of $11.44. The company has a market cap of $604.31 million, a price-to-earnings ratio of -0.86 and a beta of 1.93. Immunome, Inc. has a twelve month low of $6.94 and a twelve month high of $26.70.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The business had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. On average, sell-side analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Analyst Upgrades and Downgrades

IMNM has been the topic of a number of recent research reports. Stephens reiterated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Guggenheim lowered their target price on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a report on Thursday, March 20th. Finally, Lifesci Capital started coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of “Buy” and a consensus target price of $25.50.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.